The Marijuana Company of America (MCOA) announced on Tuesday that the United States Patent and Trademark Office had approved a patent for the company’s proprietary cannabidiol (CBD) formulation, hempSMART Brain.
The Escondido-based hemp research and development firm filed for the patent in July of 2016.
“This patent award signifies advances we achieved and are continuing to work toward as a company to produce products of the highest quality,” said MCOA CEO Donald Steinberg in a press release. “As we continue to build the hempSMART brand on a global basis, our receipt of this patent will provide the company with the recognition of the advances being made at Marijuana Company of America.”
According to the patent, the formulation is designed to prevent or treat mood disorders, memory loss, seizures, difficulty concentrating, insomnia, attention deficit disorder, autism, brain fog, post-concussion syndrome, migraine headaches, neuropathy, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, and other dementia disorders.
“Having been involved with this application from the beginning, it is rewarding to see the U.S. Patent Office recognize the unique and innovative values of the Company’s personal wellness products utilizing cannabidiol and other synergistic ingredients,” said legal project manager for the patent application, Trevor Muehlfelder. “This is our first patent to date and corroborates the company’s continuing commitment to developing natural wellness products utilizing CBD for everyone.”
In addition to CBD, the formulation contains ingredients with natural anti-inflammatory properties such as astaxanthin, and alpha-glyceryl phosphorylcholine which has shown promise as a treatment for Alzheimer’s disease and other similar conditions.
